2 recruiting, 1 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 2, Completed 1 |
Follow Advanced Urothelial Carcinoma: new trials by email Literature Review of Advanced Urothelial Carcinoma trials Research Report on Advanced Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma SHR-A2102 for Injection, Docetaxel Injection, Paclitaxel Injection - Advanced Urothelial Carcinoma | Phase 3 | Recruiting | Shanghai Hengrui Pharmaceutical Co., Ltd. | 402 | 2025-02-12 | 2025-07-17 |
| A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer 9MW2821, Chemotherapy - Advanced Urothelial Carcinoma | Phase 3 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 432 | 2023-12-29 | 2025-04-13 |
| Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Bevacizumab, Cisplatin, Gemcitabine Hydrochloride - Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 506 | 2009-07-15 | 2026-06-24 |
Carcinoma, Transitional Cell (1) · Prostatic Neoplasms (1) · Ureteral Neoplasms (1) · Urethral Neoplasms (1)
Carcinoma (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Prostatic Diseases (1) · Ureteral Diseases (1) · Urethral Diseases (1) · Urogenital Diseases (1)
Gemcitabine (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Bevacizumab (1) · Cisplatin (1) · Disulfides (1) · Docetaxel (1) · Drug Therapy (1) · Immunoglobulin G (1) · Injections (1) · Paclitaxel (1) · Pemetrexed (1) · Platinum (1)
Mabwell (Shanghai) Bioscience Co., Ltd. (1) · National Cancer Institute (NCI) (1) · Shanghai Hengrui Pharmaceutical Co., Ltd. (1)
China (2) · Puerto Rico (1) · United States (1)
PMID 33989025, PMID 40256659, PMID 40288679, PMID 40591902
U10CA031946 (1), U10CA180821 (1)